Cargando…

Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients

BACKGROUND: Programmed death 1 (PD-1) and the ligand of PD-1 (PD-L1) are central targets for immune-checkpoint therapy (ICT) blocking immune evasion-related pathways elicited by tumor cells. A number of PD-1 inhibitors have been developed, but the efficacy of these inhibitors varies considerably and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Chao, Fang, Wenfeng, Xu, Liqin, Gao, Fangfang, Hou, Yong, Zou, Hua, Ma, Yuxiang, Moll, Janne Marie, Yang, Yunpeng, Wang, Dan, Huang, Yan, Ren, Huahui, Zhao, Hongyun, Qin, Shishang, Zhong, Huanzi, Li, Junhua, Liu, Sheng, Yang, Huanming, Wang, Jian, Brix, Susanne, Kristiansen, Karsten, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069064/ https://www.ncbi.nlm.nih.gov/pubmed/35530307 http://dx.doi.org/10.3389/fonc.2022.837525

Ejemplares similares

Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
por: Xu, Liqin, et al.
Publicado: (2022)

Assessment of fecal DNA extraction protocols for metagenomic studies
por: Yang, Fangming, et al.
Publicado: (2020)

Assessment of the cPAS-based BGISEQ-500 platform for metagenomic sequencing
por: Fang, Chao, et al.
Publicado: (2017)

A novel affordable reagent for room temperature storage and transport of fecal samples for metagenomic analyses
por: Han, Mo, et al.
Publicado: (2018)

Distinct gut metagenomics and metaproteomics signatures in prediabetics and treatment-naïve type 2 diabetics
por: Zhong, Huanzi, et al.
Publicado: (2019)

An Expanded Gene Catalog of Mouse Gut Metagenomes
por: Zhu, Jiahui, et al.
Publicado: (2021)

The metagenome of the female upper reproductive tract
por: Li, Fei, et al.
Publicado: (2018)

A genome-wide association study for gut metagenome in Chinese adults illuminates complex diseases
por: Liu, Xiaomin, et al.
Publicado: (2021)

Impact of early events and lifestyle on the gut microbiota and metabolic phenotypes in young school-age children
por: Zhong, Huanzi, et al.
Publicado: (2019)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

MetaPGN: a pipeline for construction and graphical visualization of annotated pangenome networks
por: Peng, Ye, et al.
Publicado: (2018)

Small Intestinal Tuft Cell Activity Associates With Energy Metabolism in Diet-Induced Obesity
por: Arora, Pankaj, et al.
Publicado: (2021)

Effect of Caloric Restriction on BMI, Gut Microbiota, and Blood Amino Acid Levels in Non-Obese Adults
por: Zou, Hua, et al.
Publicado: (2020)

Combinatorial assessment of ctDNA release and mutational burden predicts anti‐PD(L)1 therapy outcome in nonsmall‐cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2020)

Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial
por: Zhang, Xiuying, et al.
Publicado: (2022)

Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma
por: Ali, Wael A. S., et al.
Publicado: (2023)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Phase I study of camrelizumab in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2021)

Metagenome-wide association of gut microbiome features for schizophrenia
por: Zhu, Feng, et al.
Publicado: (2020)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
por: Sheng, Jin, et al.
Publicado: (2016)

Lipidomic profiling reveals distinct differences in plasma lipid composition in healthy, prediabetic, and type 2 diabetic individuals
por: Zhong, Huanzi, et al.
Publicado: (2017)

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
por: Zhang, Xuanye, et al.
Publicado: (2019)

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy
por: He, Li-na, et al.
Publicado: (2021)

Erratum: Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
por: Sheng, Jin, et al.
Publicado: (2016)

PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
por: Fang, Wenfeng, et al.
Publicado: (2015)

Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment
por: Gu, Yanyun, et al.
Publicado: (2017)

Thermophilic microbial cellulose decomposition and methanogenesis pathways recharacterized by metatranscriptomic and metagenomic analysis
por: Xia, Yu, et al.
Publicado: (2014)

Systems-wide effects of short-term feed deprivation in obese mice
por: Andersen, Daniel, et al.
Publicado: (2021)

Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor
por: He, Li-Na, et al.
Publicado: (2023)

A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
por: Ma, Yuxiang, et al.
Publicado: (2019)

A gene catalogue of the Sprague-Dawley rat gut metagenome
por: Pan, Hudan, et al.
Publicado: (2018)

Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients
por: Ma, Yuxiang, et al.
Publicado: (2020)

Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer
por: Wang, Yixing, et al.
Publicado: (2023)

Over 50,000 Metagenomically Assembled Draft Genomes for the Human Oral Microbiome Reveal New Taxa
por: Zhu, Jie, et al.
Publicado: (2022)

Alterations in the human gut microbiome associated with Helicobacter pylori infection
por: Wang, Daoming, et al.
Publicado: (2019)

Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients
por: Zhong, Huanzi, et al.
Publicado: (2021)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2r7rj759fdmhhtij6um4a7istt